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Effect of Captopril and Enalapril on Left Ventricular Geometry, 
Function and Collagen During Healing After Anterior and Inferior 
Myocardial Infarction in a Dog Model 
BODH I. JUGDUTT,  MD, MSc, FACC 
Edmonton, Alberta, Canada 
Objectives. This study compared the effects of captopril and 
enalapril on left ventricular geometry, function and mass and on 
scar collagen and topography during healing after anterior and 
inferior myocardial infarction in a canine model. 
Background. The beneficial effect of prolonged angiotensin- 
converting enzyme inhibitor therapy on remodeling during heal- 
ing after myocardial infarction might be greater in anterior than 
inferior infarcts and more effective with captopril than enalapril 
therapy. 
Methods. The effects of 6 weeks of therapy with captopril (50 mg 
twice a day), enalapril (2.5 mg twice a day) or placebo n in vivo 
variables of left ventricular remodeling, function and mass (by 
echocardiography), emodynamic function, postmortem topogra- 
phy (by planimetry) and collagen (hydroxyproline levels) were 
studied in 36 instrumented dogs randomized to receive therapy 
48 h after left anterior descending or left circumflex coronary 
artery occlusion. 
Results. Compared with placebo therapy, both captopril and 
enalapril decreased infarct expansion and thinning, progressive 
ventricular dilation, ventricular mass and asynergy and infarct 
collagen levels in anterior and inferior infarcts. Despite similar 
small scar sizes, the effects on remodeling and dysfunction were 
greater in anterior than inferior infarcts. In addition, captopril 
produced greater attenuation ofinfarct expansion and ventricular 
enlargement, greater improvement in volume jection fraction 
and less decrease in infarct collagen levels than enalapril. 
Conclusions. On balance, captopril and enalaprii attenuated 
left ventricular emodeling and preserved function in small 
anterior and inferior infarcts despite differences in the effects of 
the drugs on individual remodeling variables. Further studies will 
be needed to determine whether inhibition of infarct collagen 
might be harmful, or differences between captopril and enalapril 
therapy important, in large transmural infarctions. 
(JAm Coil Cardiol 1995;25:1718-25) 
Inhibition of angiotensin-converting e zyme after myocardial 
infarction has the potential for limiting certain remodeling 
variables and preserving function (1-7). Although angiotensin- 
converting enzyme inhibitor therapy is recommended after 
anterior infarction in patients at high risk for left ventricular 
dilation and dysfunction (8), there has been no systematic 
comparison of its effects on anterior versus inferior infarction. 
Whether angiotensin-converting e zyme inhibitors containing 
thiol (e.g., captopril) are more effective than those without 
thiol (e.g., enalapril) is controversial (9-12). Because these 
agents inhibit hypertrophy and fibrosis during postinfarction 
healing (13-17) in noninfarcted myocardium, they might also 
increase collagen degradation and inhibit collagen deposition 
in infarct zones, interfere with scar formation or cause regres- 
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sion of the fibrous scar tissue. It is also not known whether this 
effect might promote remodeling and impair functional im- 
provement. 
Therefore, we compared the effects of therapy with the 
angiotensin-converting e zyme inhibitors captopril and enala- 
pril during healing after anterior and inferior myocardial 
infarction on remodeling variables, systolic function, ventricu- 
lar mass and infarct collagen content in a well defined canine 
model (15). 
Methods  
Experimental preparation. The experiments were ap- 
proved by the institutional animal welfare committee and 
conformed to the "Position of the American Heart Association 
on Research Animal Use" adopted by the Association in 
November 1984. Fifty healthy mongrel dogs (16 to 29 kg) were 
chronically instrumented through a left lateral thoracotomy 
under general anesthesia (sodium pentobarbital, 30 mg/kg 
body weight intravenously), as described previously (3,4). 
Polyethylene catheters were inserted in the external jugular 
vein, internal carotid artery and left atrium, filled with hepa- 
rinized saline solution and their ends brought out behind the 
neck. The mid-left anterior descending coronary artery (n = 
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25) or mid-left circumflex coronary artery (n = 25) was ligated 
with a silk thread. Pairs of metal beads were sutured on 
anterior, lateral and posterior surfaces of the epicardium at the 
mid-left ventricular level for consistent echocardiographic 
imaging. Visible epicardial collateral vessels were ligated to 
produce more transmural infarction (mean [+SD] 83 _+ 4% of 
wall thickness), as done previously (18). After closure of the 
pericardium and chest, penicillin (1 million U) and streptomy- 
cin (1 g) were given intramuscularly. 
Protocol. Two days after ligation, 48 healthy survivors were 
randomized to receive placebo (n = 16), captopril (50 rag) 
(n = 16) or enalapril (2.5 rag) (n = 16). Each group had eight 
dogs with a ligated left anterior descending coronary artery and 
eight with a ligated left circumflex coronary artery. Therapy 
was given orally, twice daily (every 12 h) for 6 weeks. The dogs 
• were given free access to fluids, and no attempt was made to 
treat heart failure. At 6 weeks, the 36 surviving dogs were 
anesthetized and the hearts were arrested in diastole with an 
overdose of intravenous potassium chloride, excised, washed in 
normal saline solution and weighed. 
In vivo measurements during healing. As described previ- 
ously (3,4), simultaneous two-dimensional echocardiograms 
(Toshiba SSH-65A [3.5-MHz transducer]), electrocardiograms 
(Gould recorder ) and hemodynamic variables (Statham 
P23Db for left atrial and arterial pressures) were recorded in 
the conscious state with the dogs standing in a sling for 
support: before therapy at 2 days after ligation, during therapy 
at 3 and 6 weeks after ligation; and again 1 to 2 days after 
therapy was stopped. Hemodynamic variables were also mea- 
sured at 1 week. Recordings during therapy were made 3 to 4 h 
after the first daily doses. Echocardiograms were acquired at 
parasternal long- and short-axis views at the mitral, chordal, 
midpapillary, low papillary and apical levels and apical four- 
and two-chamber views. 
Analysis of echocardiograms. As described previously 
(3,4), coded echocardiograms were analyzed on video playback 
(0.5-in. tapes) by two independent observers who were un- 
aware of the randomization procedures for in vivo topographic 
variables; differences were resolved by consensus. Briefly, 
endocardial and epicardial outlines of the left ventricular 
images at end-diastole and end-systole were traced with a light 
pen (Diasonics CardioRevue Center) and copied onto plastic 
overlays. Anatomic landmarks, such as papillary muscles and 
right and left ventricular junctions, were indicated on the 
tracings. Asynergy, defined as akinesia (no systolic inward 
motion and thickening) or dyskinesia (systolic outward motion 
and thinning), or both, was marked on each endocardial 
diastolic outline. The circumferential extent of asynergy on 
each short-axis view was then digitized (Hewlett-Packard 
9878A and 9835A) and used to compute total endocardial 
surface area of asynergy by a three-dimensional reconstruction 
algorithm. Outlines from five short-axis and two long-axis 
views were also used to compute volumes by means of a 
modified Simpson's rule algorithm. Global ejection fraction was 
calculated as end-diastolic volume minus end-systolic volume 
divided by end-diastolic volume. Interobserver ror was <5% in 
marking asynergy, segment length, wall thickness and areas of 
outlines, in agreement with previous studies (3,4,18). Topo- 
graphic measurements were made on end-diastolic outlines of 
short-axis images at the papillary level, and the expansion 
index (ratio of the lengths of asynergic, or infarct-containing, 
segments to nonasynergic, or non-infarct-containing, seg- 
ments) and thinning ratio (ratio of average thicknesses of the 
asynergic to nonasynergic zones) were computed. Left ventric- 
ular aneurysm was defined as the presence of a bulge in diastole 
and further bulging in systole. Left ventricular mass was calcu- 
lated by multiplying the volume of myocardium (difference in 
volumes of epicardial and endocardial shells at end-diastole) 
by an assumed specific gravity of 1.05 g/ml (19). 
Postmortem measurement of scar size, geometry and col- 
lagen content. As described previously (3,4), the risk region 
was measured on postmortem coronary arteriograms recorded 
on whole-heart and transverse section (1- to 1.5-cm thick) 
radiographs. Outlines of left ventricular rings, risk regions and 
infarct scars were made on plastic overlays and subjected to 
computerized planimetry (Hewlett-Packard 9835A computer 
and 9874A digitizer interfaced with a VAX 750 computer) to 
assess infarct size and topography and to calculate the "thin- 
ning" ratio (ratio of average thickness of infarcted wall to 
average thickness of normal wall) and "expansion" index (ratio 
of endocardial lengths of infarct-containing to non-infarct- 
containing segments demarcated by papillary muscles). Aver- 
age short-axis topographic maps were made for each group 
(3,4). Histopathologic analysis of extent of infarct scar and 
collagen content (20) was performed on a 5-mm slice from the 
middle of the infarct zone, and triplicate 5-/xm thick sections 
were stained with hematoxylin-eosin, Mallory's stain or Mas- 
son's trichrome, respectively. Myocardial hydroxyproline (mg/g 
dry tissue weight), a marker for collagen, was measured in 100- 
to 200-mg samples from the center and border egions of the 
infarct scar (after excision of normal tissue on gross examina- 
tion) and the center of the noninfarct region (20). 
Statistics. Data were analyzed in blinded manner by 1) 
analysis of variance for the significance of difference within and 
between groups; 2) chi-square test for the significance of 
difference in event frequency between groups; and 3) repeated 
measures analysis of variance for comparison of serial data 
within groups. Results are presented as mean value _+ SD, 
unless otherwise stated. Statistical significance was set at p < 
0.05 (two-tailed). 
Resu l ts  
Study groups. Of the 48 dogs that were randomized at 2 
days, 12 died over the 6 weeks (placebo n = 4, captopril n = 4, 
enalapril n = 4). The 36 dogs that were killed at 6 weeks (12 in 
each group) form the basis of this report. The distribution of 
dogs with anterior versus inferior infarction in each of the 
three groups was 6 anterior and 6 inferior in the placebo group; 
8 anterior and 4 inferior in the captopril group; and 6 each in 
the enalapril group. 
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Infarct scar size. At 6 weeks, infarct scar size with captopril 
(5 - 3 g) and enalapril (4 _+ 2 g) was not significantly less than 
that with placebo (6 _ 3 g), and heart size was 5 -+ 3 g (7 -+ 4% 
of the left ventricle, or 35 +- 16% of the risk region). 
Ventricular and risk region mass was similar (77 -+ 15 and 15 _ 
7 g, respectively). Infarct scar, ventricular and risk region size 
for anterior and inferior infarction subgroups was also similar 
(p = NS). 
Regional collagen content. Non-infarct region collagen 
content was slightly lower (p < 0.05) for enalapril than for 
placebo, but the difference between captopril and placebo did 
not achieve statistical significance. In contrast, collagen con- 
tent in the infarct center and border regions was markedly 
lower with captopril and enalapril than with placebo, and the 
decrease was greater with enalapril (Fig. 1). There was no 
difference in infarct or noninfarct collagen content between 
anterior and inferior infarction subgroups. 
I-Iemodynamic changes. The 2-day baseline hemodynamie 
changes were similar for all treatment groups and subgroups 
for all 36 dogs (heart rate 137 - 21 beats/min; mean arterial 
pressure 111 _+ 15 mm Hg; left atrial pressure 15 ___ I mm Hg). 
On day 2, captopril and enalapril produced amarked ecrease 
in left atrial pressure (20% to 40%), a mild decrease in mean 
arterial pressure (5% to 10%) but no change in heart rate 
compared with that during placebo. Although these variables 
decreased in all groups between 2 days and 6 weeks, left atrial 
and arterial pressures remained lower with angiotensin- 
converting enzyme inhibition than with placebo, and only the 
decrease in mean arterial pressure with captopril was statisti- 
cally significant (Table 1). Although the overall decrease in 
mean arterial pressure was slightly greater with captopril than 
enalapril (-14 vs. -7%), and the overall decrease in mean left 
atrial pressure was slightly less with captopril than with enala- 
pril (-34 vs. -49%), these differences were not statistically 
significant (p < 0.2 and p < 0.1, respectively). After drug 
withdrawal at 6 weeks, arterial and left atrial pressures in- 
creased in the captopril and enalapril groups, such that the 
changes in arterial ( -4% vs. -1% vs. -1%) and atrial (-31% 
vs. -26% vs. -28%) pressures from baseline were similar in 
the captopril, enalapril and placebo groups, respectively. There 
was no difference in hemodynamic changes between the ante- 
rior and inferior infarction subgroups. 
Left ventricular geometry. The effects on geometry are 
depicted in Figures 2 to 4. Compared with placebo, captopril 
and enalapril decreased regional infarct expansion (Fig. 2), 
infarct thinning (Fig. 3) and left ventricular diastolic volumes 
(Fig. 4). The placebo subgroup with anterior infarction showed 
greater elongation of the infarct-containing segment and 
greater increase in expansion index (Fig. 2), noninfarct wall 
thickness (Fig. 3), end-diastolic and end-systolic volumes and 
diastolic endocardial surface area (Fig. 4) than the placebo 
subgroup with inferior infarction. In addition, the antiremod- 
eling effects on infarct expansion and ventricular enlargement 
tended to be greater with captopril than enalapril, especially 
between 3 and 6 weeks (Fig. 2 to 4). 
Left ventricular function. Compared with placebo, capto- 
pril and enalapril decreased regional left ventricular asynergy, 
but the effect was more marked in the anterior infarction 
subgroup (Fig. 5). The decrease in total left ventricular asyn- 
ergy was less pronounced (Fig. 5). The improvement in global 
volume ejection fraction was greater with captopril than with 
enalapril in both anterior and inferior infarction subgroups 
Table 1. Percent Changes in Hemodynamic Variables From Two-Day Baseline Value* 
Heart Rate (beats/min) Mean Arterial Pressure (mm Hg) Mean Left Atrial Pressure (mm Hg) 
Group 1 wk 3 wk 6 wk 1 wk 3 wk 6 wk 1 wk 3 wk 6 wk 
Placebo (n = 12) -16 -+ 16 -20 _+ 14 -26 + 15 2 -+ 12 1 _+ 9 -1  + 7 -5  _+ 14 -23 -+ 25 -30 _+ 22 
Captopril (n = 12) -22 _+ 16 -21 _+ 17 -30 -+ 16 -9  _+ 13"~ -15 _+ 11:~ -22 -+ 31t -22 _+ 12§ -33 -+ 33 -46 -+ 18 
Enalapril (n = 12) -14 -+ 16 -16 -+ 18 -32 -+ 14 -8  -+ 13 -7  -+ 21 -5  _+ 30 -41 _+ 35t -52 - 16§ -53 -L-_ 24t 
*Decreases (minus ign) are significant versus the within-group 2-day value (p <_ 0.05). tP < 0.05, :~p < 0,001, §p < 0.005, captopril or enalapril groups versus 
placebo group. Data presented are mean value _+ SD. 
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Figure 2. Effect of therapy on in vivo changes in infarct expansion. 
Results are mean value +- SEM; points are offset around time lines for 
clarity. D = day; pdw = post drug withdrawal; W - week. *p <_ 0.05, 
anterior versus inferior infarction subgroups. ~'p _< 0.05, enalapril (T) 
or captopril (&) versus placebo (e). ~p _< 0.05, captopril versus 
enalapril. 
(Fig. 5). The frequency of left ventricular aneurysm at 6 weeks 
was lower in the inferior than anterior placebo subgroup (3 of 
6 vs. 6 of 6, p < 0.1), the anterior captopril than anterior 
placebo subgroup (2 of 8 vs. 6 of 6, p < 0.01) and the combined 
captopril than placebo groups (3 of 12 vs. 9 of 12, p < 0.025). 
The frequency of left vcntricular aneurysm was not signifi- 
cantly different for placebo versus enalapril or captopril versus 
enalapril. 
Figure 3. Effect of therapy on in vivo changes in infarct hinning. 
Results are mean value _+ SEM; points are offset around time lines for 
clarity. *p _< 0.05, anterior versus inferior infarction subgroups. ?p< 
0.05, enalapril or captopril versus placebo. ~p _< 0.05, captopril versus 
enalapril. Abbreviations and symbols as in Figure 2. 
2O 
g 
10 
,,< o 
(~-10 
-20 
-30  
'° F 
Ol- 
_o -2o l -  
INFARCT WALL NON-INFARCT WALL THINNING RATIO 
THICKNESS THICKNESS 1 1 
t 
; I i 1 21D I r i ; i I i 
D 3W 6W pdw 3W 6W pdw D 3W 6W pdw 
Left ventricular mass. Compared with placebo, both cap- 
topril (-2% vs. +2%, p = 0.5) and enalapril (-10% vs. +2%, 
p = 0.2) lowered left ventricular mass, but only enalapril 
achieved statistical significance in the anterior infarction sub- 
group (-11% + 17% vs. +12% +_ 14%, p < 0.05). 
Postmortem topography. Topographic maps in the short- 
axis view at 6 weeks confirmed less cavity area, infarct wall 
thinning, noninfarct wall thickness and infarct zone bulging 
with inferior than anterior infarction and with captopril or 
enalapril than with placebo (Table 2). The cavity area was 
larger with enalapril than captopril for both anterior and 
inferior infarction (Table 2), supporting the in vivo finding in 
Figure 4. 
Discuss ion  
There were four major findings in this study: 1) further 
infarct expansion, infarct hinning and ventricular enlargement 
occurred between 2 days and 6 weeks with infarcts at both 
anterior and inferior locations in the placebo group. Although 
there was no difference in extent of infarct hinning at the two 
infarct locations, the extent infarct expansion and ventricular 
enlargement was greater in anterior than inferior infarction. 2) 
Captopril and enalapril therapy improved left ventricular 
geometry and function between 2days and 6 weeks after both 
anterior and inferior infarction. However, the magnitude of 
the effects on expansion and ventricular enlargement were 
greater in anterior than inferior infarction. In addition, the 
effects on expansion, volumes and global function tended to be 
greater with captopril than enalapril. 3) Captopril and enala- 
pril decreased left ventricular mass in anterior and inferior 
infarction, but only the decrease with enalapril in anterior 
infarction was statistically significant. 4) Captopril and enala- 
pril decreased infarct collagen content, but the effect was more 
marked with enalapril. Enalapril also produced a mild de- 
crease in noninfarct collagen content. 
Mechanisms. Both captopril and enalapril decreased left 
atrial (index of preload) and mean arterial pressures (index of 
afterload), left ventricular volumes and left ventricular and 
infarct collagen content in anterior and inferior infarction. 
Four main mechanisms explain the effects common to the two 
angiotensin-converting enzyme inhibitors: 1) Angiotensin- 
converting enzyme inhibitors mediate vasodilation by inhibi- 
tion of angiotensin II formation and bradykinin breakdown 
and increased bradykinin, nitric oxide (21), prostaglandin E 2 
and prostacyclin (22). Vasodilation, in turn, leads to left 
ventricular unloading, less regional bulging, smaller chamber 
size and lower diastolic wall stress (by virtue of the Laplace 
law), less wall stretch, less gene expression of contractile and 
noncontractile proteins and less hypertrophy (23,24). 2) These 
agents inhibit tissue angiotensin-converting enzyme and in- 
tramyocardial conversion of angiotensin I to angiotensin II,
thereby decreasing local angiotensin II; activities of myocyte, 
fibroblast and transforming-growth factors (25-27); myocyte 
hypertrophy; and collagen deposition. Release of nitric oxide 
secondary to increased bradykinin might also inhibit myocyte 
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Figure 4. Effect of therapy on in vivo changes inleft ventric- 
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hypertrophy (28). 3) Angiotensin-converting enzyme inhibitors 
improve nutrient flow through bradykinin and nitric oxide- 
mediated ilation of coronary arteries and collateral vessels as 
well as reduced endocardial compression secondary to de- 
creased iastolic wall stress (3,4). 4) Because high myocardial 
wall stress and low nutrient flow cause matrix disruption 
(29,30), lowering diastolic wall stress and increasing flow with 
angiotensin-converting e zyme inhibition would tend to pre- 
serve the supporting matrix, improve the mechanical coupling 
between collagen fibrils at infarct scar borders and live myo- 
cytes (31), limit remodeling and preserve function. 
Figure 5. Effect of therapy on in vivo changes inregional nd global 
left ventricular function. Results are mean value _+ SEM; points are 
offset around time lines for clarity. *p _< 0.05, anterior versus inferior 
infarction subgroups. ?p< 0.05, enalapril or captopril versus placebo. 
~p _< 0.05, captopril versus enalapril. Abbreviations and symbols as in 
Figure 2. 
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Several differences between the effects of the two angiotensin- 
converting enzyme inhibitors in this study might relate to 
differences in their chemistry and pharmacology (32). 
1) Captopril, unlike enalapril, has a sulfhydryl group that 
additionally causes direct vasodilation (10) and increases va- 
sodilatory prostaglandins. These effects might explain the 
slightly greater decrease in blood pressure with captopril. 
Although the oxygen-free radical scavenging activity of the 
sulfhydryl group is protective after eperfusion (11), its role in 
this permanent occlusion model is not clear. 
2) Although captopril is itself the active drug, enalapril has 
to undergo hepatic deesterification to the active form, enala- 
prilat. Also, whereas captopril Undergoes metabolism todisul- 
fides and primarily urinary excretion, enalaprilat is excreted in 
urine (61%) and feces (33%) without further metabolism. 
Enalapril therefore has a slower onset (2 vs. 0.5 h), later peak 
(6 vs. 1 h) and longer duration (24 vs. 6 h) of action than 
captopril, and the elimination half-life is longer (>30 vs. 1.7 h). 
Although the finding of a greater decrease in ventricular mass 
with enalapril despite a lesser decrease in blood pressure 
suggests an exaggerated response with this drug, it is also 
possible that ventricular unloading was sustained for a longer 
period between doses with enalapril. Because both drugs 
produced unloading at the doses used and have flat dose- 
response curves, it is unlikely that doses used played a major 
role in the differences. 
3) Enalapril possesses greater angiotensin-converting en-
zyme inhibitory potency and more binding sites (seven vs. five) 
than captopril (32). It might produce greater inhibition of 
angiotensin II, fibroblast growth factor and transforming- 
growth factor-beta 1 than captopril. This might explain why 
enalapril (but not captopril) produced a decrease innoninfarct 
collagen and why enalapril decreased infarct scar collagen 
more than captopril. The finding that both agents produced 
marked lowering of collagen in the infarct scar region but little 
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Table 2. Mean (-+SD) Postmortem Measurements a  Low Papillary Level on Short-Axis 
Topographic Maps 
Placebo Captopril Enalapril 
Anterior infarction subgroup 
No. of dogs 6 8 6 
Angular extent of infarct (0 °) 121 _+ 5 81 _+ 9* 90 _+ 5* 
Infarct wall thickness (mm) 5 -+ 1 9 + 1' 9 _+ 1' 
Noninfarct wall thickness (mm) 15 _+ 1 11 _+ 1' 10 -+ 1" 
LV cavity area (cm 2) 5.2 -+ 0.8 2.6 _+ 0.6* 3.5 _+ 0.5*t 
Area of endocardial bulge (cm 2) 1.3 _+ 0.9 0.2 + 0.1" 0.5 _+ 0.1' 
Inferior infarction subgroup 
No. of dogs 6 4 6 
Angular extent of infarct (0 °) 105 _+ 2 76 -+ 5* 80 _+ 3* 
Infarct wall thickness (ram) 6 -+ 1 9 _+ 1" 9 _+ 1" 
Noninfarct wall thickness (mm) 14 _+ 1 11 _+ 1' 10 -+ 1" 
LV cavity area (cm 2) 4.6 _+ 0.5 2.5 + 0.5* 3.2 _+ 0.4*t 
Area of endocardial bulge (cm 2) 1.0 _+ 0.8 0.2 _+ 0* 0.3 _+ 0* 
*p _< 0.05, captopril or enalapril versus placebo, tP < 0.05, enalapril versus captopril. LV = left ventricular. 
decrease in collagen in the nonscar egion also suggests that 
angiotensin-converting e zyme inhibition might preferentially 
block collagen deposition i areas where it actively occurs, as in 
the healing infarct scar. The greater inhibition of infarct 
collagen with enalapril might explain why infarct stretching 
and ventricular enlargement were greater and why there was 
less improvement in global ejection fraction than with capto- 
pril. It is possible that low infarct collagen content might 
weaken the scar and be potentially harmful by allowing reater 
remodeling under the effect of mechanical forces (33) and by 
causing defective mechanical coupling at the infarct borders. 
Whether increased collagenase activity might have played a 
role is not known. However, no marked eleterious effect was 
found with the small infarcts in this study. 
To our knowledge, a decrease in infarct collagen with 
long-term angiotensin-converting enzyme inhibition has not 
been reported previously. Although regression of fibrous tissue 
and decreased deposition or increased egradation f collagen 
with angiotensin-converting e zyme inhibitors is thought to be 
beneficial in pressure overload hypertrophy (34), a similar 
effect on noninfarct collagen in "volume overload hypertro- 
phy" after infarction (13-17,25) was thought o be harmful 
(15), In the rat infarction model, which is associated with 
extensive necrosis of the left ventricular free wall, marked 
chamber dilation, hypertrophy and fibrosis of the septum, early 
(14) but not late (16), captopril therapy inhibited eoxyribo- 
nucleic acid synthesis, fibroblast proliferation and collagen 
deposition i  noninfarct regions. In the same model, a similar 
effect was demonstrated with perindopril (13), and nearly 
complete inhibition of noninfarct ollagen was produced by the 
angiotensin II type I receptor blocker losartan (17). In con- 
trast, the dog infarction model in this study was associated with 
only mild hypertrophy and very little increase in noninfarct 
collagen. 
Merits and limitations. The dog model allowed in vivo 
quantitation f major emodeling variables during healing over 
6 weeks as well as postmortem apping of topography and 
quantitation of infarct and noninfarct collagen content in the 
same animals. However, the infarcts were small, and 83% were 
transmural. As reported previously (19,20), infarcts shrink 
during healing from -20% of the left ventricle on day 1 to 10% 
at 6 weeks. Matrix disruption (18) and remodeling (19) would 
probably have been more severe if the infarcts were large and 
100% transmural. Although echo-opaque beads were im- 
planted for consistent serial imaging (3,4,18,19), we could not 
detect adverse effects on in vivo bulging or aneurysm with 
either angiotensin-converting e zyme inhibitor. Although 
postmortem easurements were made on hearts that were 
arrested in diastole and fixed in distension, no significant 
differences in regional bulging or thinning were detected 
between captopril and enalapril. In contrast to previous tudies 
with captopril (3,4), where transmural samples were used and 
no significant decrease in infarct collagen was detected, the 
infarct scar tissue in the present study was carefully excised for 
the collagen assays to minimize admixture with normal tissue. 
Matrix ultrastructure, collagenase activity or mechanical prop- 
erties of the scar were not studied. 
Implications. The goal of antiremodeling therapy during 
infarct healing is to preserve left ventricular geometry, prevent 
dilation and preserve function. A short, thick and strong scar 
might be desirable. The overall results of the present study 
suggest hat the final outcome with angiotensin-converting 
enzyme inhibitor therapy represents a balance of positive and 
negative ffects on factors involved in healing and remodeling 
after infarction (33). The results also suggest that antihyper- 
trophic and collagen-lowering effects might be more potent 
with enalapril than captopril. Although reduced infarct colla- 
gen did not seem to have a marked negative impact on the 
small nontransmural infarcts in this study, one might expect a 
different outcome with large transmural infarcts, as was found 
in the rat model (15). Because patients in clinical trials of 
angiotensin-converting enzyme inhibitors after infarction re- 
ceived other early therapies, and because the trials included 
thrombolysis n -30% to 70% of patients, the infarcts were 
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most likely also small and subendocardial. The finding of a 
survival benefit in most of these studies (33) supports the 
concept hat final outcome represents a balance of effects. 
However, the current data do not favor one angiotensin- 
converting enzyme inhibitor over another. Although captopril 
was associated with decreased mortality in the Survival and 
Ventricular Enlargement (SAVE) (6) and International Study 
of Infarct Survival (ISIS-4) (35) trials and with attenuation of
ventricular enlargement in a SAVE substudy (7) and other 
remodeling studies (5,36-38), survival benefit was also found 
with ramipril in the Acute Infarction Ramipril Etficacy (AIRE) 
trial (39) and with lisinopril in the Gruppo Italiano per lo 
Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) 
trial (40). Although no survival benefit was found with enala- 
pril in the Studies of Left Ventricular Dysfunction (SOLVD) 
(41) and Cooperative North Scandinavian Enalapril Survival 
Study (CONSENSUS II) (42) trials, the recent "Practical" 
study (43) that compared captopril and enalapril after infarc- 
tion showed that both agents attenuated left ventricular dila- 
tion and improved ejection fraction, but only enalapril im- 
proved survival. 
Conclusions. In the present study, therapy with captopril 
or enalapril during healing of relatively small nontransmural 
anterior and inferior myocardial infarctions limited remodel- 
ing, improved systolic function and preserved left ventricular 
geometry at 6 weeks despite a marked decrease in infarct 
collagen content. The beneficial effects on remodeling and 
function were greater in anterior than inferior infarction. 
Although the greater enalapril-induced lowering of infarct 
collagen might explain the lesser improvement in global sys- 
tolic function than that induced by captopril, it did not seem to 
have a marked negative impact on in vivo remodeling varia- 
bles. Whether the infarct-collagen lowering effect of angiotensin- 
converting enzyme inhibition might be potentially harmful 
during early healing of large transmural infarctions needs 
further study. 
I am grateful to Dr. Mohammad I. Khan for assistance with analysis of 
echocardiograms and Catherine Graham for typing the manuscript. 
References 
1. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic aptopril therapy 
on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95. 
2. Pfeffcr MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental 
myocardial infarction: beneficial effects of long-term therapy with captopril. 
Circulation 1985;72:406-12. 
3. Jugdutt BI, Schwarz-Michorowski BL, Khan MI. Effect of long-term capto- 
pril therapy on left ventricular remodeling and function during healing and 
canine myocardial infarction. J Am Coll Cardiol 1992;19:713-21. 
4. Jugdutt BI, Humen DP, Khan MI, Schwarz-Michorowski BL. Effect of left 
ventricular unloading with captopril on remodelling and function during 
healing of anterior transmural myocardial infarction in the dog. Can J 
Cardiol 1992;8:151-63. 
5. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of 
captopril on progressive ventricnlar dilatation after anterior myocardial 
infarction. N Engl J Med 1988;319:80-6. 
6. Pfeffer MA, Braunwald E, Moy6 LA, et al. on behalf of the SAVE 
Investigators. Effect of captopril on mortality and morbidity in patients with 
left ventricular dysfunction after myocardial infarction. N Engl J Med 
1992;327:669-77. 
7. St. John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two- 
dimensional echocardiographic measurements are major predictors of ad- 
verse cardiovascular events after acute myocardial infarction: the protective 
effects of captopril. Circulation 1994;89:68-75. 
8. Pfeffer MA, Braunwald E. Ventricnlar remodeling after myocardial infarc- 
tion: experimental observations and clinical implications. Circulation 1990; 
81:1161-72. 
9. Li K, Chert X. Protective ffects of captopril and enalapril on myocardial 
ischemia nd reperfusion damage of rat. J Mol Cell Cardiol 1987;19:909-15. 
10. van Grist WH, Seholtens E, de Graeff PA, de Langen CD, Wesseling H. 
Differential influences of angiotensin-converting e zyme inhibitors on the 
coronary circulation. Circulation 1988;77 Suppl I:I-24-9. 
11. Westlin W, Mullane K. Does captopril attenuate r perfusion-induced myo- 
cardial dysftmction by scavenging free radicals? Circulation 1988;77 Suppl 
I:I-30-9. 
12. van Wijngaarden J, Pinto YM, van Gilst WH, de Graeff PA, De Langen 
CDJ, Wesseling H. Converting enzyme inhibition after experimental myo- 
cardial infarction in rats: comparative study between spirapril and zofeno- 
pril. Cardiovasc Res 1991;25:936-42. 
13. Michel JB, Lattion AL, Salzmann JL, et al. Hormonal and cardiac effects of 
converting enzyme inhibition in rat myocardial infarction. Circ Res 1988;62: 
641-50. 
14. van Krimpen C, Schoemaker RG, Cleutjens JPM, et al. Angiotensin I 
converting enzyme inhibitors and cardiac remodeling. Basic Res Cardiol 
1991;86:149-55. 
15. Schoemaker RG, Debcts JJM, Struyker-Boudier HAJ, Smits JFM. Delayed 
but not immediate captopril therapy improved cardiac function in conscious 
rats, following myocardial infarction. J Mol Cell Cardiol 1991;23:187-97. 
16. Litwin SE, Litwin CM, Raya TE, Warner AL, Goldman S. Contractility and 
stiffness of non-infarcted myocardium after coronary ligation in rats. Effects 
of chronic angiotensin converting enzyme inhibition. Circulation. 1991;83: 
1028-37. 
17. Stairs JFM, van Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen 
MJAP. Angiotensin II receptor blockade after myocardial infarction in rats: 
effects on hemodynamics, myocardial DNA synthesis, and interstitial colla- 
gen content. J Cardiovasc Pharmacol 1992;20:772-8. 
18. Jugdutt BI, Tang S-B, Khan MI, Basualdo CA. Functional impact of 
remodeling during healing after non-Q wave versus Q wave anterior 
myocardial infarction in the dog. J Am Coil Cardiol 1992;20:722-31. 
19. Jugdntt BI, Khan MI. Effect of prolonged nitrate therapy on left ventricular 
remodeling after canine acute myocardial infarction. Circulation 1994;89: 
2297-307. 
20. Jugdutt BI, Amy RWM. Healing after myocardial infarction in the dog: 
changes in infarct hydroxyproline and topography. J Am Coil Cardiol 
1986;7:91-102. 
21. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the 
biological activity of endothelium-derived r laxing factor. Nature 1987;327: 
524-6. 
22. Needleman P, Marshall GR, Sobel BE. Hormone interactions in the isolated 
rabbit heart: synthesis and coronary vasomotor effects of prostaglandins, 
angiotensin and bradykinin. Circ Res 1975;37:802--8. 
23. Schneider MD, Parker TG. Cardiac myocytes as targets for the action of 
growth factors. Circulation 1990;81:1443-56. 
24. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene 
expression during myocardial growth and hypertrophy: molecular studies of 
an adaptive physiologic response. FASEB J 1991;5:3037-46. 
25. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue specific 
activation of cardiac angiotensin converting enzyme in experimental heart 
failure. Circ Res 1991;69:475-82. 
26. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced 
hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: 
critical role of the AT 1 receptor subtype. Circ Res 1993;73:413-23. 
27. Thompson NL, Bazoberry F, Speir EH, et al. Transforming rowth factor 
betaa in acute myocardial infarction in rats. Growth Factors 1988;1:91-9. 
28. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic 
guanosine monophosphate inhibit mitogenesis and proliferation of cultured 
rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7. 
29. Fujiwara H, Ashraf M, Sato S, Millard R. Transmural cellular damage and 
blood flow distribution in early ischemia in pig heart. Circ Res 1982;51:683-93. 
JACC Vol. 25, No. 7 JUGDUTT 1725 
June 1995:1718-25 CAPTOPRIL VERSUS ENALAPRIL AFTER INFARCTION 
30. Zhao M, Zhang H, Robinson TF, et al. Profound structural alterations of the 
extracellular collagen matrix in postischemic dysfunctional ("stunned") but 
viable myocardium. J Am Coll Cardiol 1987;10:1322-34. 
31. Whittaker P, Boughner DR, Kloner RA. Analysis of healing after myocardial 
infarction using polarized light microscopy. Am J Pathol 1989;34:879-93. 
32. Raia JJ, Barone JA, Byerly WG, Lacy CR. Angiotensin-converting 
enzyme inhibitors: a comparative r view. DICP Ann Pharmacother 1990; 
24:506--25. 
33. Jugdutt BI. Prevention ofventricutar remodelling post myocardial infarction: 
timing and duration of therapy. Can J Cardiol 1993;9:103-14. 
34. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. 
Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83: 
1849-65. 
35. ISIS Collaborative Group. ISIS-4: randomization of oral isosorbide mono- 
nitrate in over 50,000 patients with suspected acute myocardial infarction 
[abstract]. Circulation 1993;88 Suppl I:I-394. 
36. Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricutar 
dysfunction after myocardial infarction with angiotensin-converting e zyme 
inhibition. Lancet 1991;337:872-6. 
37. Oldroyd KG, Pye MP, Ray SG, et al. Effects of early captopril administration 
on infarct expansion, left ventricular remodelling and exercise capacity after 
acute myocardial infarction. Am J Cardiol 1991;68:713-8. 
38. Nabel EG, Topoi EJ, Galaena A, et al. A placebo-controlled trial of 
combined early intravenous captopril and recombinant tissue-type plasmin- 
ogen activator in acute myocardial infarction. J Am Coil Cardiol 1991;17: 
467-73. 
39. Ball SG. The acute infarction ramiprit efficacy (AIRE) study investigators. 
Effect of ramipril on mortality and morbidity of acute myocardial infarction 
with clinical evidence of heart failure. Lancet 1993;342:821-8. 
40. Gruppo Italiano per lo Studio della Sopravvivenza nell'fnfarcto Miocardico. 
GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and 
together on 6-week mortality and ventricular function after acute myocardial 
infarction. Lancet 1994;343:1115-22. 
41. Yusuf S. The SOLVD Investigators. Effect of enalapril on mortality and the 
development of heart failure in asymptomatic patients with reduced left 
ventricular ejection fractions. N Engl J Med 1992;327:685-91. 
42. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H, for the 
CONSENSUS II Study Group. Effects of early administration ofenatapril on 
mortality in patients with acute myocardial infarction: results of the co- 
operative North Scandinavian Enalapril Survival Study II (CONSENSUS 
II). N Engl J Med 1992;327:678-84. 
43. Foy SG, Crozier IG, Turner JG, et al. Comparison of enalapril versus 
captopril on left ventricular function and survival three months after acute 
myocardial infarction (the "Practical" Study). Am J Cardio11994;73:1180 - 6. 
